Skip to main content

Table 2 Univariate analysis

From: Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience

 

Median OS

(months)

2-year OS

(%)

p-Value

ARTT line

  

0.583

 I line

33.2

88.2

 

 II-III line

36.5

75

 

PSA reduction

  

0.553

 < 50%

33.2

80

 

 ≥ 50%

35.6

79.2

 

RT technique

  

0.502

 SBRT

35.8

80

 

 3DRT

34.3

79.2

 

RT and ARTT

  

0.101

 < 6 months

37.5

73.3

 

 > 6 months

46.6

92.9

 
 

Median PFS

(months)

2-year PFS

(%)

p-Value

ARTT line

  

0.4

 I line

14.9

40.3

 

 II-III line

14.2

32.4

 

PSA reduction

  

0.872

 < 50%

26

60

 

 ≥ 50%

14.2

32.9

 

RT technique

  

0.765

 SBRT

20.4

60

 

 3DCRT

11.6

33.9

 

RT and ARTT

  

< 0.001

 < 6 months

7.9

8

 

 > 6 months

27.7

68.8

 
  1. ARTT Androgen Receptor Targeted Therapy, RT Radiotherapy,
  2. SBRT Stereotactic Body Radiotherapy, 3DCRT Conformal radiotherapy,
  3. OS Overall Survival, PFS Progression Free Survival,
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us